Immunology Drug Market: Global Industry Analysis and Forecast (2021-2027) is segmented By Drug Class type and Disease Condition.

Immunology Drug Market size was valued at US$ 85.74 Mn. in 2020 and the total revenue is expected to grow at CAGR 8.1 % through 2021 to 2027, reaching nearly US$ 158.69 Mn.

Immunology Drug Market Overview:

Immunology drugs modify the immune response by enhancing and suppressing the immune. They are used to fight infection, prevent or treat immunological disorders. The rise in awareness regarding immunological disease in both developed and developing countries and the growing prevalence of immunological disorders because of environmental changes and changing lifestyles these factors are responsible for propelling the market growth. Some of the key market players are constantly focusing on innovation and upgrading their product portfolio for better treatment outcomes for the patients. This is also estimated to grow further during the forecast period. Over 1.2 Mn people suffer from moderate to severe plaque psoriasis currently around 6% of the patients are being treated with biologics this presents of significant opportunity for the drug manufacturers. Immunology Drug Market To know about the Research Methodology :- Request Free Sample Report 2020 is considered as a base year to forecast the market from 2021 to 2027. 2020’s market size is estimated on real numbers and outputs of the key players and major players across the globe. Past five years trends are considered while forecasting the market through 2027. 2020 is a year of exception and analyzed specially with the impact of lockdown by region.

Immunology Drug Market Dynamics:

Increasing various type of environmental factors including exposure to the toxic chemical, stress, dietary component, and infection gives rise to a large patient pool suffering from autoimmune disease. According to research by the National Stem Cell Foundation, nearly 4% of the world's population is getting affected by one or more than 80 different autoimmune diseases. The increasing prevalence of viral infection in shrimp farming has increased the high demands of autoimmune disease and its Diagnostics. In February 2021, Sandoz Canada introduced adalimumab (HUMIRA) bio similar, Hyrimoz, in Canada. The company confirmed that the drug received approval and provide high efficacy to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, adult Crohn’s disease, and adult uveitis, among others. The rising number of successful clinical trials is driving the demand for biological several companies to invest in Research and Development to develop biosimilar and affordable and effective imitation of the biological drugs hence the Increasing demand for such products. In September 2020, Lupin launched generic Rheumatoid Arthritis drug, Leflunomide, in the US, this is estimated to derive the market growth during the forecast period. Additionally, these drugs are associated with various adverse effects such as infection, Allergic reaction, Muscle ache Fever and fast irregular pounding, and others. Hence these factors and the reimbursement policies in developing regions hamper the market growth during the forecast period.

Immunology Drug Market Segment Analysis:

The Immunology Drug Market is segmented By Drug Class type and Disease Condition. Based on the Drug Class Type, The Immunology Drug Market is segmented into Monoclonal antibodies, Fusion proteins, Immunosuppressant, Polyclonal Antibody. The monoclonal Antibody segment is dominated by the Immunology Drug Market with the highest market share of 38% in the year 2020. The dominance is attributed to the established clinical efficiency of monoclonal antibodies such as adalimumab, rituximab, and treatment of rare and chronic conditions and autoimmune diseases. In Addition to this higher number of approvals for these drugs. Increase sing adoption of immunosuppressant’s in developing nations because of their higher treatment efficacy contributes to their faster growth rate. Immunology Drug Market Based on the Disease Condition, The Immunology Drug Market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Inflammatory Bowel Disease, and Prophylaxis of Organ Rejection. The Rheumatoid Arthritis segment dominated the market with the highest CAGR of 3.4% in the year 2020. This segment is also expected to grow with the highest market share of xx% in the year 2020. Increasing prevalence of Rheumatoid Arthritis and rising number of patients, expected to increase the demand for Rheumatoid Arthritis treatment. According to the regional and national database, the global incidence of Rheumatoid Arthritis is around 3 cases per 10,000, whereas the global prevalence is estimated at 1% to 2% of the total population. Immunology Drug Market

Immunology Drug Market Regional Insights:

North America dominated the Immunology Drug Market with the largest market share of 40% in 2020. It is also expected to register highest at a CAGR of xx% during the forecast period. The presence of well-established healthcare infrastructure, higher prevalence of chronic conditions and comparatively higher diagnosis and treatment rates among the patient population in the U.s are the factors responsible for the dominance of the region in the global market. Europe is anticipated to register a significant CAGR during the forecasting period. Rising prevalence of autoimmune conditions and increase drug approval in the region, For example in 2019 estimated 40,000 people in the UK were suffering from Rheumatoid Arthritis and 4 Mn people were suffering from autoimmune disease. The market in the Asia Pacific is expected to grow at the highest CAGR of XX% during the forecasting period. Asia Pacific region is expected to hold the highest CAGR of around 2.3% during the forecast period. Rising obesity in people and increasing geriatric population especially in developing countries such as China and India are increasing the demand for the Immunology Drug Market. Europe Immunology Drug Market is expected to at steady rate during the forecast period. The objective of the report is to present a comprehensive analysis of the Immunology Drug Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also helps in understanding the Immunology Drug Market dynamic, structure by analyzing the market segments and project the Immunology Drug Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Immunology Drug Market make the report investor’s guide.

Immunology Drug Market Scope: Inquire before buying

Immunology Drug Market

Immunology Drug Market, by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Immunology Drug Market Key Players

Pfizer Inc. • F. Hoffmann-La Roche Ltd.) • AbbVie, Inc. • Bristol-Myers Squibb Company • Merck Sharp & Dohme Corp. • Novartis AG • Janssen Global Services, LLC • Amgen Inc • Astellas Pharma Inc. • UCB SA • Eli Lilly and Company • Other Prominent Players • Blue Cross • Glaxismithkline • Zydus Cadillla

Frequently Asked Questions:

1] Which segments are covered in Immunology Drug Market report? Ans. The segments covered in Immunology Drug Market report are based on Disease By Drug Class and By Disease Condition. 2] Which region is expected to hold the highest share in the Immunology Drug Market? Ans. North America is expected to hold the highest share in the Vision Screeners Market. 3] What is the market size of Immunology Drug Market by 2027? Ans. The market size of Immunology Drug Market by 2027 is US $ 158.69 Mn. 4] Who are the top key players in the Immunology Drug Market? Ans. Active Biotech, Eli Lilly and Company, Autoimmune Inc, Pfizer, GlaxoSmithKline plc, Seattle Genetics, Genentech, F. Hoffmann-La Roche Ltd., Eisai Co., Bayer AG, Sanofi Aventis LLC. 5] What was the market size of Immunology Drug Market in 2020? Ans. The market size of Immunology Drug Market in 2020 was US $ 85.74 Mn.
Immunology Drug Market size was valued at US$ 85.74 Mn. in 2020 and the total revenue is expected to grow at CAGR 8.1 % through 2021 to 2027, reaching nearly US$ 158.69 Mn.

Immunology Drug Market Overview:

Immunology drugs modify the immune response by enhancing and suppressing the immune. They are used to fight infection, prevent or treat immunological disorders. The rise in awareness regarding immunological disease in both developed and developing countries and the growing prevalence of immunological disorders because of environmental changes and changing lifestyles these factors are responsible for propelling the market growth. Some of the key market players are constantly focusing on innovation and upgrading their product portfolio for better treatment outcomes for the patients. This is also estimated to grow further during the forecast period. Over 1.2 Mn people suffer from moderate to severe plaque psoriasis currently around 6% of the patients are being treated with biologics this presents of significant opportunity for the drug manufacturers. Immunology Drug Market To know about the Research Methodology :- Request Free Sample Report 2020 is considered as a base year to forecast the market from 2021 to 2027. 2020’s market size is estimated on real numbers and outputs of the key players and major players across the globe. Past five years trends are considered while forecasting the market through 2027. 2020 is a year of exception and analyzed specially with the impact of lockdown by region.

Immunology Drug Market Dynamics:

Increasing various type of environmental factors including exposure to the toxic chemical, stress, dietary component, and infection gives rise to a large patient pool suffering from autoimmune disease. According to research by the National Stem Cell Foundation, nearly 4% of the world's population is getting affected by one or more than 80 different autoimmune diseases. The increasing prevalence of viral infection in shrimp farming has increased the high demands of autoimmune disease and its Diagnostics. In February 2021, Sandoz Canada introduced adalimumab (HUMIRA) bio similar, Hyrimoz, in Canada. The company confirmed that the drug received approval and provide high efficacy to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, adult Crohn’s disease, and adult uveitis, among others. The rising number of successful clinical trials is driving the demand for biological several companies to invest in Research and Development to develop biosimilar and affordable and effective imitation of the biological drugs hence the Increasing demand for such products. In September 2020, Lupin launched generic Rheumatoid Arthritis drug, Leflunomide, in the US, this is estimated to derive the market growth during the forecast period. Additionally, these drugs are associated with various adverse effects such as infection, Allergic reaction, Muscle ache Fever and fast irregular pounding, and others. Hence these factors and the reimbursement policies in developing regions hamper the market growth during the forecast period.

Immunology Drug Market Segment Analysis:

The Immunology Drug Market is segmented By Drug Class type and Disease Condition. Based on the Drug Class Type, The Immunology Drug Market is segmented into Monoclonal antibodies, Fusion proteins, Immunosuppressant, Polyclonal Antibody. The monoclonal Antibody segment is dominated by the Immunology Drug Market with the highest market share of 38% in the year 2020. The dominance is attributed to the established clinical efficiency of monoclonal antibodies such as adalimumab, rituximab, and treatment of rare and chronic conditions and autoimmune diseases. In Addition to this higher number of approvals for these drugs. Increase sing adoption of immunosuppressant’s in developing nations because of their higher treatment efficacy contributes to their faster growth rate. Immunology Drug Market Based on the Disease Condition, The Immunology Drug Market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Inflammatory Bowel Disease, and Prophylaxis of Organ Rejection. The Rheumatoid Arthritis segment dominated the market with the highest CAGR of 3.4% in the year 2020. This segment is also expected to grow with the highest market share of xx% in the year 2020. Increasing prevalence of Rheumatoid Arthritis and rising number of patients, expected to increase the demand for Rheumatoid Arthritis treatment. According to the regional and national database, the global incidence of Rheumatoid Arthritis is around 3 cases per 10,000, whereas the global prevalence is estimated at 1% to 2% of the total population. Immunology Drug Market

Immunology Drug Market Regional Insights:

North America dominated the Immunology Drug Market with the largest market share of 40% in 2020. It is also expected to register highest at a CAGR of xx% during the forecast period. The presence of well-established healthcare infrastructure, higher prevalence of chronic conditions and comparatively higher diagnosis and treatment rates among the patient population in the U.s are the factors responsible for the dominance of the region in the global market. Europe is anticipated to register a significant CAGR during the forecasting period. Rising prevalence of autoimmune conditions and increase drug approval in the region, For example in 2019 estimated 40,000 people in the UK were suffering from Rheumatoid Arthritis and 4 Mn people were suffering from autoimmune disease. The market in the Asia Pacific is expected to grow at the highest CAGR of XX% during the forecasting period. Asia Pacific region is expected to hold the highest CAGR of around 2.3% during the forecast period. Rising obesity in people and increasing geriatric population especially in developing countries such as China and India are increasing the demand for the Immunology Drug Market. Europe Immunology Drug Market is expected to at steady rate during the forecast period. Immunology Drug MarketThe objective of the report is to present a comprehensive analysis of the Immunology Drug Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also helps in understanding the Immunology Drug Market dynamic, structure by analyzing the market segments and project the Immunology Drug Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Immunology Drug Market make the report investor’s guide.

Immunology Drug Market Scope: Inquire before buying

Immunology Drug Market

Immunology Drug Market, by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Immunology Drug Market Key Players

Pfizer Inc. • F. Hoffmann-La Roche Ltd.) • AbbVie, Inc. • Bristol-Myers Squibb Company • Merck Sharp & Dohme Corp. • Novartis AG • Janssen Global Services, LLC • Amgen Inc • Astellas Pharma Inc. • UCB SA • Eli Lilly and Company • Other Prominent Players • Blue Cross • Glaxismithkline • Zydus Cadillla

Frequently Asked Questions:

1] Which segments are covered in Immunology Drug Market report? Ans. The segments covered in Immunology Drug Market report are based on Disease By Drug Class and By Disease Condition. 2] Which region is expected to hold the highest share in the Immunology Drug Market? Ans. North America is expected to hold the highest share in the Vision Screeners Market. 3] What is the market size of Immunology Drug Market by 2027? Ans. The market size of Immunology Drug Market by 2027 is US $ 158.69 Mn. 4] Who are the top key players in the Immunology Drug Market? Ans. Active Biotech, Eli Lilly and Company, Autoimmune Inc, Pfizer, GlaxoSmithKline plc, Seattle Genetics, Genentech, F. Hoffmann-La Roche Ltd., Eisai Co., Bayer AG, Sanofi Aventis LLC. 5] What was the market size of Immunology Drug Market in 2020? Ans. The market size of Immunology Drug Market in 2020 was US $ 85.74 Mn.

About This Report

Report ID 125678
Category Healthcare
Published Date Oct 2021
Updated Date
Contact Us